Clot Removal Procedure for Stroke With a Very Large Area of Damaged Brain
Compares clot removal plus medical care with medical care alone in stroke.
Plain-language title generated from the registry record
Registry title: Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core
Key facts
- Where
- Harbin, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden stroke caused by a blocked large brain artery and a very large area of damaged brain, seen on scans.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke with a blockage of the intracranial internal carotid artery, M1 or proximal M2 segment of the middle cerebral artery, confirmed by CTA or MRA. Scans must show ASPECTS ≤ 2 or an infarct core volume of 100 mL or more. Symptoms or last time known well must be 24 hours or less before randomization.
- Earlier treatment
- No earlier endovascular attempt for this stroke. Before the stroke, mRS must have been 0 - 1. Current treatment with direct thrombin inhibitors or factor Xa inhibitors is not allowed.
- Biomarker or test result
- Selection imaging done 3 hours or less before randomization. Core volume is measured as rCBF <30% on CTP.
Main reasons for not taking part
- Bleeding in the brain seen on CT or MRI
- Brain midline shift or herniation
- Blockage in both sides or in several vessels of the front and back brain circulation
- Blood pressure above 185/110 mmHg that medicine does not lower
- Known clotting problem (INR >1.7 or platelets <100×10⁹/L)
Read by machine on 9 November 2026.
Where in China
- he First Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Harbin Medical University
- Trial code
- NCT07791810
- Record updated
- 28 August 2026
- Original description
an investigator initiated, prospective, multicenter, randomized, open-label, blinded endpoint trial (PROBE)Read full original descriptionShow less
Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core: A Prospective, Multicenter, Randomized, Open-label, Blinded Endpoint Trial (LARGE CORE-MT)
an investigator initiated, prospective, multicenter, randomized, open-label, blinded endpoint trial (PROBE)
Inclusion: ≥18 years; Symptoms onset or Time last known well ≤ 24 h from randomization; Acute ischemic stroke due to an occlusion of the intracranial internal carotid artery, M1 or proximal M2 segment of the middle cerebral artery confirmed by CTA or MRA; NCCT or diffusion-weighted imaging (DWI) demonstrating ASPECTS ≤ 2 or infarct core volume (defined as rCBF <30% on CTP) ≥ 100 mL; Selection imaging performed ≤ 3 hours before randomization; Pre-stroke mRS 0 - 1; Informed consent form was signed.
Exclusion: Current treatment with direct thrombin inhibitors or factor Xa inhibitors; Concomitant malignancy or other conditions with life expectancy under 6 months; Prior endovascular attempt for this stroke; Evidence of intracranial hemorrhage on CT/MRI, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, or subdural/epidural hemorrhage; Patients with severe organ failure (cardiac, pulmonary, renal, or hepatic); Known coagulopathy, with international normalized ratio (INR) >1.7 or platelet count <100×10⁹/L; Cerebral midline shift or herniation, or other ventricular mass effect with midline shift as confirmed on CT/MRI; Bilateral anterior circulation or acute multi-vessel occlusion involving both anterior and posterior circulation, confirmed by CTA or MRA; Blood pressure >185/110 mmHg and is refractory to medicine; Female who is known to be pregnant; Currently participation in another clinical study; Other circumstances that the investigator considers inappropriate for participation.